Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-10T14:47:44.946Z Has data issue: false hasContentIssue false
  • English
  • Français

Quetiapine in the elderly with parkinsonism and psychosis

Published online by Cambridge University Press:  16 April 2020

H.H Wijnen ,
F.M.M.A van der Heijden ,
F.M.E van Schendel ,
S Tuinier  and
W.M.A Verhoeven
H.H Wijnen
Affiliation:
Vincent van Gogh Institute for Psychiatry, Postbus 5, 5800 AAVenray, The Netherlands
F.M.M.A van der Heijden*
Affiliation:
Vincent van Gogh Institute for Psychiatry, Postbus 5, 5800 AAVenray, The Netherlands
F.M.E van Schendel
Affiliation:
Vincent van Gogh Institute for Psychiatry, Postbus 5, 5800 AAVenray, The Netherlands
S Tuinier
Affiliation:
Vincent van Gogh Institute for Psychiatry, Postbus 5, 5800 AAVenray, The Netherlands
W.M.A Verhoeven
Affiliation:
Vincent van Gogh Institute for Psychiatry, Postbus 5, 5800 AAVenray, The Netherlands Department of Psychiatry, Erasmus University Medical Centre, Rotterdam, The Netherlands
*
*Corresponding author. E-mail address: fvanderheijden@vvgi.nl (F.M.M.A. van der Heijden).
Get access

Abstract

In the present open prospective study the effects of quetiapine were investigated in two elderly patients with parkinsonism and psychosis. Treatment induced a marked antipsychotic effect that coincided with an improvement of general motor functioning. These findings support the idea that quetiapine may be preferentially of use in the elderly with parkinson’s disease and psychotic symptoms.

Keywords

QuetiapineElderlyPsychosisParkinsonism
Type
Case report
Information
European Psychiatry , Volume 18 , Issue 7 , November 2003 , pp. 372 - 373
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Targum, SDAbbott, JL. Efficacy of quetiapine in Parkinson’s patients with psychosis. J Clin Psychopharmacol 2000;20:54–60.CrossRefGoogle ScholarPubMed
Friedman, JHFactor, SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000;15:201–11.3.0.CO;2-D>CrossRefGoogle ScholarPubMed
Fernandez, HHTrieschmann, MEBurke, MAFriedman, JH. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry 2002;63:513–5.CrossRefGoogle ScholarPubMed
Walker, ZGrace, JOvershot, RSatarasinghe, SSwan, AKatona, CLE, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999;14:459–66.3.0.CO;2-R>CrossRefGoogle ScholarPubMed
Hwang, JPYang, CHYu, HCChang, JWCheng, CYTsai, SJ. The efficacy and safety of risperidone for the treatment of geriatric psychosis. J Clin Psychopharmacol 2001;21:583–7.CrossRefGoogle ScholarPubMed
Arnt, JSkarsfeldt, T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63–101.CrossRefGoogle Scholar
Goldstein, JM. Quetiapine fumarate (Seroquel): a new atypical antipsychotic. Drugs Today 1999;35:193–210.CrossRefGoogle ScholarPubMed
Van der Heijden, FMMAVerhoeven, WMAFekkes, DSijben, AESTuinier, S. Quetiapine in relapsing schizophrenia: clinical efficacy and the effect on monoaminergic parameters. Acta Neuropsychiatr 2003;15:133–9.CrossRefGoogle ScholarPubMed
Boumann, WPPinner, G. Use of atypical antipsychotic drugs in old age psychiatry. Adv Psychiatric Treatment 2002;8:49–58.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.